Not Signed In -
Diagnostic Imaging |
CAT Scan; Computed Tomography; CT; Nuclear Medicine Tests; Radionuclide Scans |
[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Clinical Trial: Positron Emission Tomography Imaging Using Tariquidar and Technetium Tc 94m Sestamibi in Treating Patients With Cancer
This study is not yet open for patient recruitment.
Verified by National Cancer Institute (NCI) May 2006
Purpose
RATIONALE: Tariquidar may reduce tumor-cell resistance to chemotherapy drugs and allow the tumor cells to be killed. Positron emission tomography (PET) imaging using technetium Tc 94m sestamibi and tariquidar may improve the ability to detect the retention of chemotherapy drugs in cancer cells and allow doctors to plan more effective treatment.
PURPOSE: This diagnostic trial is studying PET imaging using tariquidar and technetium Tc 94 sestamibi to see how well it works in detecting the retention of chemotherapy drugs in the tumor cells of patients with cancer.
| Condition | Intervention |
|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Drug: tariquidar Drug: technetium Tc 94m sestamibi Procedure: diagnostic test Procedure: drug resistance inhibition Procedure: radionuclide imaging Procedure: tomography, emission computed |
MedlinePlus related topics: Cancer; Cancer Alternative Therapies
Genetics Home Reference related topics: Cancer
Study Type: Interventional
Study Design: Diagnostic
Official Title: Diagnostic Pilot Study of Positron-Emission Tomography Imaging Using Tariquidar as a Drug Resistance Inhibitor and Technetium Tc 94m Sestamibi in Patients With Cancer
OBJECTIVES:
Primary
- Determine the feasibility of positron-emission tomography scanning with technetium Tc 94m sestamibi in cancer patients.
Secondary
- Determine P-glycoprotein reversal in patients treated with tariquidar.
OUTLINE: This is a pilot study.
Patients receive technetium Tc 94m sestamibi IV and concurrently undergo positron-emission tomography (PET) scanning. After at least 72 hours, patients receive tariquidar IV over 30-45 minutes. Within 1-4 hours after tariquidar administration, patients undergo an additional PET scan using technetium Tc 94m sestamibi.
Patients are followed for 1 month.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 15 months.
Eligibility
DISEASE CHARACTERISTICS:
- Diagnosis of cancer
- Eligible for enrollment on an active NCI protocol for treatment of cancer
- Index lesion > 2 cm
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Weight ≤ 136 kg
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- Prior tariquidar allowed
Location and Contact Information
Susan E. Bates, MD, Principal Investigator, National Cancer Institute (NCI)
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Last Updated: June 7, 2006
Record first received: July 8, 2004
ClinicalTrials.gov Identifier: NCT00086853
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2006-07-03
Resources
- "Slice" Scanner Latest Advance in Early Detection of Heart Disease (American Heart Association)
- American College of Radiology Accredited Facilities (American College of Radiology)
email this page
print this page
bookmark this page
feedback on this page
